{"id":"W3102615618","doi":"10.25251/skin.4.supp.82","title":"Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; AstraZeneca","keywords":"Ustekinumab; Double blinded; Medicine; Placebo; Plaque psoriasis; Psoriasis; Dermatology; Randomized controlled trial; Internal medicine; Pathology; Disease; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001900549,0.0007885747,0.002557053,0.0002450597,0.0003801077,0.0008635877,0.0006261235,0.00135212,0.002597054],"category_scores_gemma":[0.001523415,0.0005520544,0.001359034,0.0002574464,0.0006992362,0.0008737572,0.0002872882,0.002576597,0.000547329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000409295,"about_ca_system_score_gemma":0.000667981,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000461048,"about_ca_topic_score_gemma":0.0008385318,"domain_scores_codex":[0.9994492,0.000287699,0.00004031251,0.00007189759,0.00006895918,0.00008194394],"domain_scores_gemma":[0.9992531,0.0002229115,0.0001673295,0.00005913278,0.00004627755,0.000251309],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.897146,0.01027758,0.003992056,0.001375144,0.001831049,0.0001017791,0.0001284437,0.0006022372,0.01469243,0.0001782548,0.001909476,0.06776553],"study_design_scores_gemma":[0.8391411,0.1349102,0.02044794,0.00008258972,0.001040958,0.0002304024,0.00005833651,0.0007717229,0.001405245,0.0002770891,0.001602846,0.00003170739],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844862,0.01103723,0.000422947,0.0005688872,0.0001966676,0.0007427503,0.0005739325,0.00008008724,0.001891278],"genre_scores_gemma":[0.993826,0.00263569,0.000628828,0.0007761436,0.0002348406,0.0004667539,0.000551998,0.00001406215,0.0008657369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002597054,"threshold_uncertainty_score":0.01005119,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01981299134265906,"score_gpt":0.255535521771845,"score_spread":0.2357225304291859,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}